557 related articles for article (PubMed ID: 29880491)
1. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Chan DC; Watts GF; Somaratne R; Wasserman SM; Scott R; Barrett PHR
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
[TBL] [Abstract][Full Text] [Related]
2. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
3. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
[TBL] [Abstract][Full Text] [Related]
4. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
Chan DC; Wong AT; Pang J; Barrett PH; Watts GF
Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
[TBL] [Abstract][Full Text] [Related]
5. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
[TBL] [Abstract][Full Text] [Related]
6. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Watts GF; Chan DC; Somaratne R; Wasserman SM; Scott R; Marcovina SM; Barrett PHR
Eur Heart J; 2018 Jul; 39(27):2577-2585. PubMed ID: 29566128
[TBL] [Abstract][Full Text] [Related]
7. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
[TBL] [Abstract][Full Text] [Related]
8. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
Hooper AJ; Heeks L; Robertson K; Champain D; Hua J; Song S; Parhofer KG; Barrett PH; van Bockxmeer FM; Burnett JR
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
[TBL] [Abstract][Full Text] [Related]
10. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
Reyes-Soffer G; Pavlyha M; Ngai C; Thomas T; Holleran S; Ramakrishnan R; Karmally W; Nandakumar R; Fontanez N; Obunike J; Marcovina SM; Lichtenstein AH; Matthan NR; Matta J; Maroccia M; Becue F; Poitiers F; Swanson B; Cowan L; Sasiela WJ; Surks HK; Ginsberg HN
Circulation; 2017 Jan; 135(4):352-362. PubMed ID: 27986651
[TBL] [Abstract][Full Text] [Related]
11. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
12. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.
Drouin-Chartier JP; Tremblay AJ; Hogue JC; Lemelin V; Lamarche B; Couture P
J Lipid Res; 2018 Aug; 59(8):1501-1509. PubMed ID: 29946054
[TBL] [Abstract][Full Text] [Related]
13. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
Karpe F; Hellénius ML; Hamsten A
Metabolism; 1999 Mar; 48(3):301-7. PubMed ID: 10094104
[TBL] [Abstract][Full Text] [Related]
14. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial.
Heidemann BE; Marais AD; Mulder MT; Visseren FLJ; Roeters van Lennep JE; Stroes ESG; Riksen NP; van Vark-van der Zee LC; Blackhurst DM; Koopal C
J Clin Lipidol; 2023; 17(5):666-676. PubMed ID: 37517914
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
16. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.
Matikainen N; Taskinen MR; Stennabb S; Lundbom N; Hakkarainen A; Vaaralahti K; Raivio T
Eur J Endocrinol; 2012 Mar; 166(3):487-92. PubMed ID: 22190000
[TBL] [Abstract][Full Text] [Related]
17. n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes.
Tremblay AJ; Lamarche B; Hogue JC; Couture P
J Diabetes Res; 2016; 2016():2909210. PubMed ID: 27034958
[TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
Parhofer KG; Laubach E; Barrett PH
J Lipid Res; 2003 Jun; 44(6):1192-8. PubMed ID: 12671031
[TBL] [Abstract][Full Text] [Related]
19. Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia.
Hooper AJ; Robertson K; Barrett PH; Parhofer KG; van Bockxmeer FM; Burnett JR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1474-8. PubMed ID: 17213276
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
Parhofer KG; Barrett PH; Schwandt P
J Clin Endocrinol Metab; 2000 Nov; 85(11):4224-30. PubMed ID: 11095458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
